** Drug developer Allakos' ALLK.O shares fall 72.7% to 33 cents premarket
** Co says its experimental drug, AK006, did not show clinical benefit in an early-stage trial testing it in patients with chronic spontaneous urticaria — a skin condition that causes itching and hives
** As a result, the company has decided to discontinue further clinical development of AK006
** Co also plans to reduce its workforce by 75%
** Co plans to retain about 15 employees to explore strategic alternatives, maintain compliance with regulatory and financial reporting requirements, and wind-down the early-stage trial
** Estimates it will have cash, cash equivalents and investments in a range of approximately $35 mln to $40 mln at June 30, 2025
** Stock had fallen 55.7% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.